Medi-Caps Q1 FY27: Consolidated loss narrows to Rs 223L, standalone posts Rs 59L loss

Pat NegativeResults RestatedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹26.55

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-2.1% vs market

Pharmaceuticals peers, median of 168sector+0.3%-2.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+0.0-2.1+0.3-2.4

Next day

+1.2-0.0+1.3+0.7+0.5

-0.6-0.2-0.4+0.6-1.2

+0.9+0.2+0.8+0.4+0.6

-0.9+0.3-1.2+1.2-2.1

+3.4+0.4+3.0+0.2+3.2

—+0.9—+0.2—

15d

—+1.6—+1.1—

—+2.0—+2.4—

—+0.6—+1.6—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medi-Caps posted Q1 FY27 results with consolidated revenue of Rs 278.69L versus Rs 268.76L YoY and net loss of Rs 223.29L, narrowed from Rs 349.19L last year. Standalone revenue was just Rs 10.49L with a loss of Rs 58.96L. Pharma division revenue was Rs 268.20L and Real Estate Rs 10.49L. Subsidiary Medgel contributed Rs 283.84L income and Rs 223.30L loss. Board approved CFO change, new Whole Time Woman Director, and CMD re-appointment. Auditor gave a clean limited review with no qualifications.

Likely market impact

Losses continue but consolidated loss narrowed from Rs 349L to Rs 223L. Pharma remains weak. Key management reshuffle done. No exceptional items.